Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Pulmonary Tuberculosis IV

Pulmonary Tuberculosis IV

Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...

Pulmonary Tuberculosis I

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...

Pulmonary Tuberculosis V

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...

Pulmonary Tuberculosis II

Pulmonary Tuberculosis II

Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...

Pulmonary Tuberculosis III

Pulmonary Tuberculosis III

Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:

Tuberculosis

Tuberculosis

Tuberculosis (TB) remains a significant global health concern, primarily targeting the lungs and spreading through airborne transmission. Infection begins when aerosolized droplet nuclei, expelled by an individual with active TB, are inhaled by another person. These microscopic particles carry Mycobacterium tuberculosis, the causative agent of TB. Upon reaching the alveoli, the bacilli are engulfed by alveolar macrophages. However, due to their specialized lipid-rich cell wall, these pathogens...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Is the stiffness of human muscle and tendon structures related to muscle fiber composition in vivo?

The Journal of sports medicine and physical fitness·2017

Same author

Preclinical study and clinical trial of a novel therapeutic vaccine against multi-drug resistant tuberculosis.

Human vaccines & immunotherapeutics·2016

Same author

Active muscle and tendon stiffness of plantar flexors in sprinters.

Journal of sports sciences·2016

Same author

[Genetic analysis reveals misidentification of Mycobacterium lentiflavum as Mycobacterium intracellulare by the COBAS TaqMan MAI test].

Kekkaku : [Tuberculosis]·2014

Same author

Rapid identification of strains belonging to the Mycobacterium abscessus group through erm(41) gene pyrosequencing.

Diagnostic microbiology and infectious disease·2014

Same author

[Comparative evaluation of acid-fast staining for the detection of Mycobacterium fortuitum--clinical performance of fluorescent and Ziehl-Neelsen staining].

Kekkaku : [Tuberculosis]·2013

Search research articles

Related Experiment Video

Updated: Jul 17, 2026

Micro-Colony Forming Unit Assay for Efficacy Evaluation of Vaccines Against Tuberculosis

Micro-Colony Forming Unit Assay for Efficacy Evaluation of Vaccines Against Tuberculosis

Published on: July 28, 2023

[Novel vaccines against M. tuberculosis].

¹Clinical Research Center, National Hospital Organization Kinki-Chuo Chest Medical Center, 1180 Nagasone-cho, Kita-ku, Sakai-shi, Osaka 591-8555, Japan. okm@kch.hosp.go.jp

Kekkaku : [Tuberculosis]

|January 24, 2007

Summary

A novel DNA vaccine combining heat shock protein 65 (HSP 65) and interleukin-12 (IL-12) shows superior protection against tuberculosis in animal models. This new tuberculosis vaccine candidate, HSP 65 + IL-12/HVJ, offers improved efficacy over the BCG vaccine.

More Related Videos

Enrichment of Native and Recombinant Extracellular Vesicles of Mycobacteria

Enrichment of Native and Recombinant Extracellular Vesicles of Mycobacteria

Published on: December 8, 2023

Protective Efficacy and Pulmonary Immune Response Following Subcutaneous and Intranasal BCG Administration in Mice

Protective Efficacy and Pulmonary Immune Response Following Subcutaneous and Intranasal BCG Administration in Mice

Published on: September 19, 2016

Related Experiment Videos

Last Updated: Jul 17, 2026

Micro-Colony Forming Unit Assay for Efficacy Evaluation of Vaccines Against Tuberculosis

Micro-Colony Forming Unit Assay for Efficacy Evaluation of Vaccines Against Tuberculosis

Published on: July 28, 2023

Enrichment of Native and Recombinant Extracellular Vesicles of Mycobacteria

Enrichment of Native and Recombinant Extracellular Vesicles of Mycobacteria

Published on: December 8, 2023

Protective Efficacy and Pulmonary Immune Response Following Subcutaneous and Intranasal BCG Administration in Mice

Protective Efficacy and Pulmonary Immune Response Following Subcutaneous and Intranasal BCG Administration in Mice

Published on: September 19, 2016

Area of Science:

Immunology
Vaccinology
Microbiology

Context:

The Bacillus Calmette-Guérin (BCG) vaccine is currently the primary vaccine for tuberculosis (TB) but has limited efficacy.
There is a global need for novel, more effective vaccines against Mycobacterium tuberculosis infection.

Purpose:

To develop and evaluate a novel DNA vaccine for tuberculosis (TB) with enhanced protective efficacy compared to BCG.
To assess the efficacy of a DNA vaccine encoding heat shock protein 65 (HSP 65) and interleukin-12 (IL-12) delivered via hemagglutinating virus of Japan (HVJ)-liposomes in preclinical models.

Summary:

A DNA vaccine, HSP 65 + IL-12/HVJ, was developed using HVJ-liposome technology, combining HSP 65 DNA and IL-12 DNA.
This vaccine demonstrated significantly higher protection against Mycobacterium tuberculosis challenge in mouse, guinea pig, and cynomolgus monkey models compared to BCG.
The vaccine induced robust cellular immune responses, including CD8+ cytotoxic T lymphocyte activity and IFN-gamma secretion, and improved survival rates in non-human primates.

Impact:

This study presents the first successful DNA vaccination against Mycobacterium tuberculosis in a non-human primate model.
The HSP 65 + IL-12/HVJ vaccine shows promise as a superior alternative to BCG for future clinical trials.
The findings support the advancement of this novel DNA vaccine towards human clinical trials for tuberculosis prevention.